FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8124人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839882, encodeId=5cfa1839882c2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, objectType=article, longId=202449, objectId=39aa20244938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39aa20244938, replyNumber=0, likeNumber=67, createdTime=2021-02-28, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39aa20244938, moduleTitle=FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39aa20244938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839910, encodeId=a799183991092, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准狼疮肾炎口服新药, objectType=article, longId=206243, objectId=686e206243af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686e206243af, replyNumber=0, likeNumber=89, createdTime=2021-06-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686e206243af, moduleTitle=FDA批准狼疮肾炎口服新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686e206243af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839791, encodeId=468c1839e917d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛, objectType=article, longId=191859, objectId=6d7f19185941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7f19185941, replyNumber=0, likeNumber=82, createdTime=2020-07-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7f19185941, moduleTitle=FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7f19185941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839876, encodeId=a12418398e601, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, objectType=article, longId=201898, objectId=555f2018985e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555f2018985e, replyNumber=0, likeNumber=57, createdTime=2021-06-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555f2018985e, moduleTitle=美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555f2018985e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839843, encodeId=128818398432f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准新型抗HIV疗法Rukobia，用于治疗选择有限的患者, objectType=article, longId=196983, objectId=e9a219698332, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9a219698332, replyNumber=0, likeNumber=61, createdTime=2020-08-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9a219698332, moduleTitle=FDA批准新型抗HIV疗法Rukobia，用于治疗选择有限的患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9a219698332)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839847, encodeId=7829183984eb4, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Humira生物类似物Hulio（adalimumab-fkjp）, objectType=article, longId=197353, objectId=402219e353f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=402219e353f8, replyNumber=0, likeNumber=92, createdTime=2021-01-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=402219e353f8, moduleTitle=FDA批准Humira生物类似物Hulio（adalimumab-fkjp）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=402219e353f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839787, encodeId=86ce1839e8755, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物, objectType=article, longId=191037, objectId=bf9e19103eb6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9e19103eb6, replyNumber=0, likeNumber=78, createdTime=2020-03-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9e19103eb6, moduleTitle=FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf9e19103eb6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839821, encodeId=664b183982180, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Tau放射性诊断剂Tauvid用于阿尔茨海默症, objectType=article, longId=194973, objectId=f4ed1949e35d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ed1949e35d, replyNumber=0, likeNumber=69, createdTime=2020-09-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ed1949e35d, moduleTitle=FDA批准Tau放射性诊断剂Tauvid用于阿尔茨海默症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ed1949e35d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839830, encodeId=dfd618398301f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准FGF23阻断抗体Crysvita，治疗肿瘤诱发性骨软化症（TIO）, objectType=article, longId=196198, objectId=80211961986e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80211961986e, replyNumber=0, likeNumber=58, createdTime=2020-09-06, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80211961986e, moduleTitle=FDA批准FGF23阻断抗体Crysvita，治疗肿瘤诱发性骨软化症（TIO）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80211961986e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839905, encodeId=8b9f183990549, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, objectType=article, longId=205805, objectId=fa1f20580549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa1f20580549, replyNumber=0, likeNumber=69, createdTime=2021-03-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa1f20580549, moduleTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa1f20580549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839781, encodeId=e02e1839e8105, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Opdivo+Yervoy二线治疗肝细胞癌被FDA批准, objectType=article, longId=190102, objectId=724a19010294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724a19010294, replyNumber=0, likeNumber=62, createdTime=2020-03-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724a19010294, moduleTitle=Opdivo+Yervoy二线治疗肝细胞癌被FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724a19010294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839913, encodeId=b2ac1839913bf, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤, objectType=article, longId=206994, objectId=d418206994cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d418206994cd, replyNumber=0, likeNumber=66, createdTime=2021-08-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d418206994cd, moduleTitle=全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d418206994cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839855, encodeId=741d18398557d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准第三款CAR-T细胞治疗产品上市, objectType=article, longId=198097, objectId=5ef419809e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ef419809e19, replyNumber=0, likeNumber=22, createdTime=2020-08-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ef419809e19, moduleTitle=FDA批准第三款CAR-T细胞治疗产品上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ef419809e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839890, encodeId=31f018398900f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症, objectType=article, longId=203465, objectId=f0b620346555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b620346555, replyNumber=0, likeNumber=64, createdTime=2021-08-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b620346555, moduleTitle=默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b620346555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839794, encodeId=efdc1839e9448, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Koselugo作为美国最佳治疗儿童1型神经纤维瘤的药物, objectType=article, longId=192011, objectId=06fc192011c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fc192011c7, replyNumber=0, likeNumber=63, createdTime=2020-06-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fc192011c7, moduleTitle=FDA批准Koselugo作为美国最佳治疗儿童1型神经纤维瘤的药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fc192011c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839871, encodeId=e3b218398e1d6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=晚期实体瘤的新希望！FDA批准MOR210 / TJ210治疗晚期实体瘤的IND, objectType=article, longId=200901, objectId=302a20090170, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=302a20090170, replyNumber=0, likeNumber=70, createdTime=2020-10-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=302a20090170, moduleTitle=晚期实体瘤的新希望！FDA批准MOR210 / TJ210治疗晚期实体瘤的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=302a20090170)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=COVID-19继发的急性肺损伤：FDA批准RLS-0071进行临床试验, objectType=article, longId=198322, objectId=c26b198322d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c26b198322d4, replyNumber=0, likeNumber=68, createdTime=2021-05-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c26b198322d4, moduleTitle=COVID-19继发的急性肺损伤：FDA批准RLS-0071进行临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c26b198322d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839851, encodeId=df64183985170, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=**脂代谢紊乱药物Triheptanoin被FDA批准上市, objectType=article, longId=197720, objectId=7ee019e72040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ee019e72040, replyNumber=0, likeNumber=85, createdTime=2020-11-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ee019e72040, moduleTitle=**脂代谢紊乱药物Triheptanoin被FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ee019e72040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839885, encodeId=603f18398855c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床, objectType=article, longId=202926, objectId=e79820292602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79820292602, replyNumber=0, likeNumber=67, createdTime=2021-02-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79820292602, moduleTitle=诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79820292602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839837, encodeId=ed2e183983e3d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准抗肿瘤药物PI3Kα抑制剂CYH33临床试验, objectType=article, longId=196559, objectId=e8de1965590d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8de1965590d, replyNumber=0, likeNumber=92, createdTime=2020-12-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8de1965590d, moduleTitle=FDA批准抗肿瘤药物PI3Kα抑制剂CYH33临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8de1965590d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准FoundationOne CDx作为Vitrakvi（larotrectinib）的伴随诊断剂，以帮助鉴定NTRK融合阳性患者

2021-02-28

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准狼疮肾炎口服新药

2021-06-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛

2020-07-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准欧狄沃®（纳武利尤单抗）联合伊匹木单抗成为且目前**获批的免疫疗法，用于既往未经治疗的、不可切除的恶性胸膜间皮瘤患者

2021-06-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准新型抗HIV疗法Rukobia，用于治疗选择有限的患者

2020-08-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Humira生物类似物Hulio（adalimumab-fkjp）

2021-01-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准S1P受体调控剂ozanimod用于多发性硬化症药物

2020-03-31

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Tau放射性诊断剂Tauvid用于阿尔茨海默症

2020-09-02

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准FGF23阻断抗体Crysvita，治疗肿瘤诱发性骨软化症（TIO）

2020-09-06

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤

2021-03-01

仁者大医 (审核中...)

前往app查看评论内容

#FDA批准#

Opdivo+Yervoy二线治疗肝细胞癌被FDA批准

2020-03-31

bugit (审核中...)

前往app查看评论内容

#FDA批准#

全球**每日1次口服PI3K/CK1抑制剂获FDA批准上市，治疗淋巴瘤

2021-08-31

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准第三款CAR-T细胞治疗产品上市

2020-08-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症

2021-08-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Koselugo作为美国最佳治疗儿童1型神经纤维瘤的药物

2020-06-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

晚期实体瘤的新希望！FDA批准MOR210 / TJ210治疗晚期实体瘤的IND

2020-10-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

COVID-19继发的急性肺损伤：FDA批准RLS-0071进行临床试验

2021-05-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

**脂代谢紊乱药物Triheptanoin被FDA批准上市

2020-11-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

诺诚健华奥布替尼获FDA批准开展治疗多发性硬化症II期临床

2021-02-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准抗肿瘤药物PI3Kα抑制剂CYH33临床试验

2020-12-17

科室
- - 订阅+
  - 更多科室
工具
服务